# Danwang Medical Technology Shanghai Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/danwang-medical-technology-shanghai-co

- Industry: Healthcare
- Headquarters: Hangzhou, China
- Total disclosed funding: $19M
- Latest round: Series A (Sep 1, 2021)
- Investors on record: 5

## About

Established in 2019 and based in Shanghai, China, D1med operates an organoid technology developer that focuses on tumor diagnosis and treatment field. It cooperates with Merck China, Fudan University, Shanghai Jiao Tong University, and Shanghai Pulmonary Hospital. The founder, Guoqiang Guoqiang graduated from Fudan University and has published his research work in Cell Stem Cell and CancerResearch. In December 2024, the company closed a strategic investment led by new investor Sinowisdom.

The company's business can be categorized into tumor personalized precision therapy, drug company R&D services, Patient in the Lab organ-like disease model library, and IVD reagents and automation equipment. It has also developed organoid service platforms for new drug research and development companies, such as Next Generation Diagnostics of Organoid, Next Generation Drug Diagnostics Platform of Organoid, and Next Generation Culture of Organoid.

Danwang Medical Technology Shanghai Co., Ltd. generates revenue by clinical development and application of organoid technology.

## Funding rounds

- Series A, Sep 1, 2021, $19M — Co-Win Ventures, Delian Capital, Shanhai Capital, Yushan Partners, Shanghai Growth Investment
- Angel, Feb 8, 2021 — Co-Win Ventures, Yushan Partners

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel, Series A
- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Angel, Series A
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series A
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series A